Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

BACKGROUND: Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in pre...

詳細記述

保存先:
書誌詳細
主要な著者: Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L., Engelman, Jeffrey A.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079055/
https://ncbi.nlm.nih.gov/pubmed/24670165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1311107
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料